Cmv glycoproteins and recombinant vectors
AssigneeOregon Health & Science University
InventorsLouis PICKER, Klaus Frueh, Scott G. Hansen, Colin Powers
Life of this patent
Estimating the term…
Abstract
This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.
Claims21
A method to enable superinfection or repeated infection of an animal by a vector containing and expressing at least one cytomegalovirus (CMV) glycoprotein, wherein the glycoprotein is US2, US3, US6 or US11 of human CMV (HCMV) or the corresponding functional homologues Rh182, Rh184, Rh185 or Rh189 of rhesus CMV (RhCMV), and administering the vector into the animal, wherein the vector expresses at least one cytomegalovirus glycoprotein.
A method of determining efficacy of a CMV vaccine, comprising (a) administering a CMV vaccine to a test subject, (b) challenging the test subject with a CMV vector, wherein glycoproteins within the US2 to US11 region of CMV are deleted from the CMV vector, and wherein the CMV vector contains and expresses at least one immunogen of the CMV vaccine, and (c) measuring a CD8+ T cell response, wherein the CMV vaccine is efficacious if a CD8+ T cell response is protective against the challenge with the CMV vector lacking the glycoproteins within the US2 to US11 region of CMV and wherein the CMV vector contains and expresses at least one immunogen of the CMV vaccine.
A method of inducing a pathogen-specific CD8+ T cell response in an animal, comprising administering a CMV vector wherein the CMV vector contains and expresses at least one pathogen-derived immunogen, wherein the CD8+ T cell response in the animal confer protection against the pathogen.
A method of inducing a different pathogen-specific CD8+ T cell response in an animal, comprising administering a CMV vector with at least one cytomegalovirus (CMV) glycoprotein deleted from the CMV vector, wherein the glycoprotein is US2, US3, US6 or US11, and wherein the CMV vector contains and expresses at least one pathogen-derived immunogen, wherein the CD8+ T cell response in the animal differs as compared to a CMV vaccine with a CMV vector that contains and expresses the same immunogen and wherein a CMV glycoprotein is not deleted from the CMV vector.
Dependencies are inferred from the claim text.